Canaccord analyst Richard Close raised the firm's price target on Clover Health to $4.20 from $3.20 and keeps a Buy rating on the shares. The firm said its 2026 thesis is playing out as managed care rising tide is liftng both employer and payer digital health boats as strong performance in April and May has led to decent appreciation.
